Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Mesenchymal stem cells as a novel vaccine platform.

Tomchuck SL, Norton EB, Garry RF, Bunnell BA, Morris CA, Freytag LC, Clements JD.

Front Cell Infect Microbiol. 2012 Nov 16;2:140. doi: 10.3389/fcimb.2012.00140. eCollection 2012.

2.

Fish vaccine antigens produced or delivered by recombinant DNA technologies.

Leong JC, Anderson E, Bootland LM, Chiou PW, Johnson M, Kim C, Mourich D, Trobridge G.

Dev Biol Stand. 1997;90:267-77. Review.

PMID:
9270855
4.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

5.

Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Ryder AB, Nachbagauer R, Buonocore L, Palese P, Krammer F, Rose JK.

J Virol. 2015 Dec 16;90(5):2544-50. doi: 10.1128/JVI.02598-15.

6.

Applications and challenges of multivalent recombinant vaccines.

Naim HY.

Hum Vaccin Immunother. 2013 Mar;9(3):457-61. Epub 2012 Dec 18. Review.

7.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
8.

Heat-shock proteins as dendritic cell-targeting vaccines--getting warmer.

McNulty S, Colaco CA, Blandford LE, Bailey CR, Baschieri S, Todryk S.

Immunology. 2013 Aug;139(4):407-15. doi: 10.1111/imm.12104. Review.

9.

Vaccines expressing the innate immune modulator EAT-2 elicit potent effector memory T lymphocyte responses despite pre-existing vaccine immunity.

Aldhamen YA, Seregin SS, Schuldt NJ, Rastall DP, Liu CJ, Godbehere S, Amalfitano A.

J Immunol. 2012 Aug 1;189(3):1349-59. doi: 10.4049/jimmunol.1200736. Epub 2012 Jun 27.

10.

Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.

Brown TH, David J, Acosta-Ramirez E, Moore JM, Lee S, Zhong G, Hancock RE, Xing Z, Halperin SA, Wang J.

Vaccine. 2012 Jan 5;30(2):350-60. doi: 10.1016/j.vaccine.2011.10.086. Epub 2011 Nov 8.

PMID:
22075089
11.

Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.

Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A.

Expert Rev Vaccines. 2013 Apr;12(4):379-93. doi: 10.1586/erv.13.15. Review.

PMID:
23560919
12.
13.

The impact of new technologies on vaccine development.

Winther MD, Dougan G.

Biotechnol Genet Eng Rev. 1984;2:1-39. Review.

PMID:
6085856
14.

Recombinant vaccine delivery systems and encoded vaccines.

Stover CK.

Curr Opin Immunol. 1994 Aug;6(4):568-71. Review.

PMID:
7946044
15.

Pre-existing immunity against vaccine vectors--friend or foe?

Saxena M, Van TT, Baird FJ, Coloe PJ, Smooker PM.

Microbiology. 2013 Jan;159(Pt 1):1-11. doi: 10.1099/mic.0.049601-0. Epub 2012 Nov 22. Review.

16.

Listeria as a vaccine vector.

Bruhn KW, Craft N, Miller JF.

Microbes Infect. 2007 Aug;9(10):1226-35. Epub 2007 May 7. Review.

PMID:
17719258
17.

Comparison of vaccine efficacy for different antigen delivery systems for infectious pancreatic necrosis virus vaccines in Atlantic salmon (Salmo salar L.) in a cohabitation challenge model.

Munang'andu HM, Fredriksen BN, Mutoloki S, Brudeseth B, Kuo TY, Marjara IS, Dalmo RA, Evensen Ø.

Vaccine. 2012 Jun 8;30(27):4007-16. doi: 10.1016/j.vaccine.2012.04.039. Epub 2012 Apr 23.

PMID:
22537985
18.

Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens.

Tsukamoto K, Saito S, Saeki S, Sato T, Tanimura N, Isobe T, Mase M, Imada T, Yuasa N, Yamaguchi S.

J Virol. 2002 Jun;76(11):5637-45.

19.

Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.

Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, Henderson LA, Schoepp RJ, Cashman KA, Hensley LE, Garry RF.

Virol J. 2010 Oct 20;7:279. doi: 10.1186/1743-422X-7-279.

20.

Swine adipose stromal cells loaded with recombinant bovine herpesvirus 4 virions expressing a foreign antigen induce potent humoral immune responses in pigs.

Donofrio G, Taddei S, Franceschi V, Capocefalo A, Cavirani S, Martinelli N, Ottonello S, Ferrari M.

Vaccine. 2011 Jan 29;29(5):867-72. doi: 10.1016/j.vaccine.2010.11.048. Epub 2010 Nov 27.

PMID:
21115049

Supplemental Content

Support Center